Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for Pediatric Leukemia

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 130-136

  Perko, Ross ^a   Kang, Guolian ^a   Sunkara, Anusha ^a   Leung, Wing ^a,b   Thomas, Paul G ^a   Dallas, Mari H ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Immune reconstitution; Infections; Leukemia; Pediatrics; T cells

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACTERIAL INFECTION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; DEATH; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GAMMA DELTA T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OVERALL SURVIVAL; PROPHYLAXIS; REMISSION; SCHOOL CHILD; SURVIVOR; TREATMENT OUTCOME; VIRUS INFECTION; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; IMMUNOLOGY; INFANT; LEUKEMIA, MYELOID, ACUTE; MORTALITY; OPPORTUNISTIC INFECTIONS; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; OPPORTUNISTIC INFECTIONS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927130854     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.027     Document Type: Article

References (32)

1. Storek J., Gooley T., Witherspoon R.P., et al. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 1997, 54:131-138.
2. Cela M.E., Holladay M.S., Rooney C.M., et al. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant 1996, 17:243-247.
3. Viale M., Ferrini S., Bacigalupo A. TCR gamma/delta positive lymphocytes after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992, 10:249-253.
4. Pfeffer K., Schoel B., Gulle H., et al. Primary responses of human T cells to mycobacteria: a frequent set of gamma/delta T cells are stimulated by protease-resistant ligands. Eur J Immunol 1990, 20:1175-1179.
5. Morita C.T., Jin C., Sarikonda G., Wang H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev 2007, 215:59-76.
6. Constant P., Davodeau F., Peyrat M.A., et al. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 1994, 264:267-270.
7. Burjanadze M., Condomines M., Reme T., et al. Invitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007, 139:206-216.
8. Ciofani M., Zuniga-Pflucker J.C. Determining gammadelta versus alphass T cell development. Nat Rev Immunol 2010, 10:657-663.
9. Ishikawa H., Naito T., Iwanaga T., et al. Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics. Immunol Rev 2007, 215:154-165.
10. Takagaki Y., Decloux A., Bonneville M., Tonegawa S. Diversity of gamma-delta T-cell receptors on murine intestinal intraepithelial lymphocytes. Nature 1989, 339:712-714.
11. Havran W.L., Chien Y.H., Allison J.P. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 1991, 252:1430-1432.
12. Groh V., Steinle A., Bauer S., Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gamma delta T cells. Science 1998, 279:1737-1740.
13. Saitoh A., Narita M., Watanabe N., et al. Anti-tumor cytotoxicity of gamma delta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 2008, 25:137-147.
14. Gertner-Dardenne J., Castellano R., Mamessier E., et al. Human V gamma 9V delta 2 T cells specifically recognize and kill acute myeloid leukemic blasts. JImmunol 2012, 188:4701-4708.
15. Castella B., Vitale C., Coscia M., Massaia M. Vgamma 9V delta 2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. Cell Mol Life Sci 2011, 68:2419-2432.
16. Lamb L.S., Henslee-Downey P.J., Parrish R.S., et al. Increased frequency of TCR gamma delta+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. JHematother 1996, 5:503-509.
17. Godder K.T., Henslee-Downey P.J., Mehta J., et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007, 39:751-757.
18. Hirokawa M., Horiuchi T., Kawabata Y., et al. Reconstitution of gammadelta T cell repertoire diversity after human allogeneic hematopoietic cell transplantation and the role of peripheral expansion of mature T cell population in the graft. Bone Marrow Transplant 2000, 26:177-185.
19. Chatzidimitriou D., Gavriilaki E., Sakellari I., Diza E. Hematopoietic cell transplantation and emerging viral infections. JMed Virol 2010, 82:528-538.
20. Scheper W., van Dorp S., Kersting S., et al. GammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013, 27:1328-1338.
21. Farnault L., Gertner-Dardenne J., Gondois-Rey F., et al. Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation. Bone Marrow Transplant 2013, 48:1478-1479.
22. Locatelli F., Bauquet A., Palumbo G., et al. Negative depletion of alpha/beta+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. Immunol Lett 2013, 155:21-23.
23. Schumm M., Lang P., Bethge W., et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013, 15:1253-1258.
24. Leung W., Campana D., Yang J., et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011, 118:223-230.
25. Prentice R.L., Kalbfleisch J.D., Peterson A.V., et al. The analysis of failure times in the presence of competing risks. Biometrics 1978, 34:541-554.
26. Gray B.M., Egan M.L., Pritchard D.G. Specificity of monoclonal antibodies against group B streptococcus type II and inhibition of their binding by human secretions. Pediatr Res 1988, 24:68-72.
27. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
28. Bonneville M., O'Brien R.L., Born W.K. Gamma delta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010, 10:467-478.
29. Mackall C.L., Fleisher T.A., Brown M.R., et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. NEngl J Med 1995, 332:143-149.
30. Porter D.L. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Hematology Am Soc Hematol Educ Program 2011, 2011:292-298.
31. Fukui Y., Oono T., Cabaniols J.P., et al. Diversity of T cell repertoire shaped by a single peptide ligand is critically affected by its amino acid residue at a T cell receptor contact. Proc Natl Acad Sci USA 2000, 97:13760-13765.
32. Wei H., Huang D., Lai X., et al. Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR. JImmunol 2008, 181:4798-4806.